Revvity Earnings: Strong Start to 2026 and Pending China Immunodiagnostic Sale Boost Shares
On May 5, Revvity announced first-quarter results that included 7% reported growth to $711 million (above FactSet consensus of $704 million,) operating margin of 23.6% (above its expectation of 23% previously,) and adjusted EPS growth of 5% to $1.06 (or above consensus of $1.02.)